Packaging: 100 grams of less than bottled, 100 grams of aluminum foil bag. Package: bottle or foil bag Long-term storage conditions: -4℃ -2℃, dry and protected from light

Somaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which has better results in the treatment of type 2 diabetes lining-up Saglutide was used for solid-liquid synthesis. Aib 8, Arg34GLP-1 (7-37) and fatty side chain acylating agent were prepared by solid phase synthesis. Lys 26 was modified with synthetic fatty chain acylating agent under alkaline conditions to obtain somallutide, and the biological activity of homemade samples was determined by time-resolved fluorescence resonance energy transfer immunoassay. Somaglutide (Semeglutide), a new GLP-1 receptor agonist drug, is a new subcutaneous weekly GLP-1 analog. Somlutide is a long-acting GLP-1 analog of 1 / w subcutaneous injection developed by Novo Nordisk. Compared with liraglutide, saglutide is longer fatty chains with increased hydrophobicity, but it is modified by modification of PEG with a short chain and has greatly enhanced hydrophilicity. PEG modification not only can bind closely with albumin, mask the hydrolysis site of DPP-4 enzyme, but also can reduce renal excretion, can prolong the biological half-life, and achieve the effect of long circulation. Novo Nordisk's somallutide suspended the DPP-4 sitagliptin, and GLP-1 originator long-acting exenatide (should be designed to lilly trulicity head to head ratio, bullying early on the market). In the trial, the high dose was A1C1.6%, and the highest weight reduction was 6kg. This trial of somaglutide examined the efficacy and safety of 1.0mg somaglutide compared to a weekly dose of 2.0mg exenatide in 813 patients with type 2 diabetes over a 56-week period of 1-2 antidiabetic drugs. In December 2017, the FDA officially approved the launch of the weekly GLP-1 hypoglycemic drug somallutide, developed by Novo Nordisk (NovoNordisk), and is known as Ozempic. According to the clinical test Chemicalbook data, Ozempic can reduce HbA 1 c levels compared with placebo, Januvia from Merck, Bydureon from AstraZeneca, and Lantus from Sanofi. The drug also shows the ability to help patients lose weight. As a leader in the field of diabetes, novo nordisk (NovoNordisk) not only in the field of insulin, the development of glucagon-like peptide-1 (GLP-1) analog pull tide (Liraglutide, trade name: Victoza), since 2009, has occupied the GLP-1 market, global sales of $3.2 billion in 2016, is fruitful. Liraraglutide compounds have expired, and generic drug companies are eyeing them. To prevent this, Novo Nordisk has already prepared the next generation of liraglutide: smarlutide. Structurally, Semeglutide is Aib at position 8 on the GLP-1 (7-37) chain, Arg at position 34 to Lys, and Lys at position 26 attached to the octadecanate fatty chain.take part in